RESTON, Va.--(BUSINESS WIRE)--Aptiv Solutions, a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials, today announced the release of ADDPLAN® DF, innovative software that designs, simulates, and analyzes Phase 2 dose finding studies to make them more efficient and effective. ADDPLAN® DF is the latest product in the ADDPLAN® family that includes a series of products for adaptive confirmatory trials. ADDPLAN® DF is a fully-validated design and analysis tool based on MCP-Mod methodology (a combination of Multiple Comparison Procedures and Modeling) and covers dose finding designs for establishing Proof of Concept and determining the optimum target dose to select for Phase 3 trials. This tool will enable drug developers to remove a number of the uncertainties inherent in Phase 2 dose finding trials and improve critical decisions on dose-selection, which will directly impact the probability of success in Phase 3.
Help employers find you! Check out all the jobs and post your resume.
